Literature DB >> 3075018

Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases.

M J Van Kroonenburgh1, E K Pauwels.   

Abstract

An overview of the literature is presented concerning the formation, detection, incidence and effect of the human immunoglobulin response on immunoscintigraphy. The following conclusions are drawn. The production of human anti-mouse antibodies (HAMAs) is associated with a diminished therapeutic response; adequate prevention of HAMA production is not yet possible; high HAMA titres give rise to rapid clearance of MoAb into the liver and marked reduction of tumour uptake which results in reduced image quality on immunoscintigraphy; alteration of antibody biodistribution is likely to be related to the in vivo formation of antibody-antibody complexes which could interfere with image quality when sequential imaging is carried out.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3075018     DOI: 10.1097/00006231-198811000-00009

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  13 in total

Review 1.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  99mTc-human immunoglobulin (HIG)--first results of a new agent for the localization of infection and inflammation.

Authors:  J R Buscombe; D Lui; G Ensing; R de Jong; P J Ell
Journal:  Eur J Nucl Med       Date:  1990

4.  Radioimmunotherapy: no news from the newcomer.

Authors:  A M Mello; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Mouse-specific antibody responses to a monoclonal antibody during repeated immunoscintigraphy investigations: comparison of antibody titres and imaging studies in a rat model.

Authors:  M V Pimm; A C Perkins; S J Gribben; A J Markham
Journal:  Eur J Nucl Med       Date:  1990

6.  Influence of syngeneic monoclonal anti-idiotypic antibodies to murine monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments.

Authors:  M V Pimm; S Demignot; S J Gribben
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.

Authors:  J S Crowe; V S Hall; M A Smith; H J Cooper; J P Tite
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

8.  Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice.

Authors:  M V Pimm; S J Gribben
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

9.  Tumor-associated antigens recognized by human monoclonal antibodies.

Authors:  H R Chang; K Koda; M E McKnight; M C Glassy
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

10.  Clinical pharmacology and tissue disposition studies of 131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88.

Authors:  M G Rosenblum; B Levin; M Roh; D Hohn; R McCabe; L Thompson; L Cheung; J L Murray
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.